Evaluating the Clinical Outcomes of Probiotic Supplementation as Adjunctive Therapy in Peptic Ulcer Management

Background: Peptic ulcer disease from H. Pylori is a big issue now, mostly because antibiotics are failing more often. Standard treatments cause frequent side effects. We looked at whether probiotics added to triple therapy could ease GI symptoms and boost quality of life. Methods: A prospective, non-interventional observational study spanned one year with 46 adults having PUD and H. Pylori infection (n=23 per group). Standard triple therapy was given to the intervention group; the non-intervention group got triple therapy plus probiotics. QOL was tracked through a modified WHOQOL-BREF across physical, psychological, and environmental aspects. GI symptoms were measured using GSRS at start and 14 days later. Results The probiotic group demonstrated significantly greater QOL improvements, with total scores rising by 24.50 points versus 8.92 points. GSRS scores improved significantly across all five domains: reflux (3.28), abdominal pain (1.99), indigestion (1.80), diarrhea (1.52), and constipation (1.02). The mean overall symptom score difference was 1.92±0.84 versus 0.59±0.89 (p=0.046). Conclusion: Probiotic supplementation alongside standard triple therapy significantly improved GI symptoms and QOL in H. pylori-infected PUD patients, confirming meaningful clinical benefits. Routine use of probiotics as adjunctive therapy in PUD management is strongly recommended.